Abstract:
:Neuroleptics are of established efficacy in mania. Controlled data on the use of olanzapine in mania is however, absent. In this study, 30 patients meeting DSM-IV criteria for mania were randomly allocated to receive either olanzapine or lithium in a 4 week double-blind randomized controlled design. There were no significant outcome differences between the two groups on any of the primary outcome measures, the Brief Psychiatric Rating Scale (lithium 28.2; olanzapine 28.0; P = 0.44); Clinical Global Impression (CGI) improvement scale (lithium 2.75, olanzapine 2.36; P = 0.163) or the Mania Scale (lithium 13.2, olanzapine 10.2; P = 0.315). Olanzapine was however, significantly superior to lithium on the CGI-severity scale at week 4 (lithium 2.83, olanzapine 2.29; P = 0.025). Olanzapine did not differ from lithium in terms of treatment emergent extrapyramidal side-effects as measured by the Simpson-Angus Scale. Olanzapine appears to be at least as effective as lithium in the treatment of mania.
journal_name
Int Clin Psychopharmacoljournal_title
International clinical psychopharmacologyauthors
Berk M,Ichim L,Brook Sdoi
10.1097/00004850-199911000-00003subject
Has Abstractpub_date
1999-11-01 00:00:00pages
339-43issue
6eissn
0268-1315issn
1473-5857journal_volume
14pub_type
临床试验,杂志文章,随机对照试验abstract::Sixteen young male volunteers received single doses of moclobemide 200 mg, moclobemide 400 mg, amitriptyline 50 mg and placebo in a double-blind crossover study. Subjects then completed a test battery which is sensitive to the effects of psychoactive drugs at 1, 2, and 4 h post-dose. The test battery included tasks of...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004850-199300810-00007
更新日期:1993-04-01 00:00:00
abstract::One of the most effective treatments for children with Attention Deficit Disorder with Hyperactivity (ADDH) has been the prescription of methylphenidate (MPH). While laboratory-based evidence indicates that MPH effects may be rate-dependent, little is known about changes evinced in operant behavior controlled by compl...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004850-198810000-00006
更新日期:1988-10-01 00:00:00
abstract::Several cardiovascular risk factors have been linked to antipsychotic treatment and cardiovascular mortality is increased in these patients compared to the general population. The full metabolic syndrome (or its components) is associated with an increased risk of cardiovascular disorders. The prevalence of the metabol...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/01.yic.0000188215.84784.17
更新日期:2006-03-01 00:00:00
abstract::One hundred and sixty patients with a primary diagnosis of obsessive-compulsive disorder were enrolled in a multicentre, randomized, double-blind, placebo-controlled study of fluvoxamine. After a placebo washout phase, patients were randomized to treatment with placebo or fluvoxamine (100-300 mg/day) for 10 weeks. Sev...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:
更新日期:1996-03-01 00:00:00
abstract::A group of 13 untreated schizophrenic patients was collected over two and a half years. They were prescribed a standard regime of oral haloperidol, and where possible were transferred to haloperidol decanoate depot injections when their clinical condition stabilised. The progress of their symptoms was monitored weekly...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:
更新日期:1986-07-01 00:00:00
abstract::In recent years the efficacy of new antipsychotics has been investigated through a number of randomized controlled trials. This paper considers some methodological flaws that affect these studies and proposes possible solutions. The final goal is the implementation of a new generation of trials with the aim of demonst...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-199903000-00012
更新日期:1999-03-01 00:00:00
abstract::Studies on humans show that depressive disorder is associated with an increased risk of developing cognitive dysfunction, and animal studies suggest that antidepressants may have neuroprotective abilities. On the basis of these observations, it was hypothesized that treatment with antidepressants may decrease the risk...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0b013e32834ace0f
更新日期:2011-11-01 00:00:00
abstract::Recent studies have shown that the use of subscales derived from the Hamilton Depression (HAM-D) rating scale are just as reliable and enhance sensitivity for detecting response and remission after antidepressant treatment. The purpose of the present study was to determine if the responses on two items of the HAM-D sc...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004850-200211000-00002
更新日期:2002-11-01 00:00:00
abstract::Premenstrual dysphoria (PMD) is a severe form of premenstrual syndrome, afflicting approximately 5% of all women of fertile age. The cardinal symptoms are irritability and anger. In addition, sadness, tension and carbohydrate craving are common complaints. The symptoms surface regularly between ovulation and menstruat...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:
更新日期:1999-05-01 00:00:00
abstract::Platelet serotonin type 2A receptor (5-HT2A) sensitivity changes have previously been documented in depression, although it is unclear if this represents a stable trait marker of the illness, or whether it represents an acute state marker of depression that would change with treatment. Electroconvulsive therapy (ECT) ...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-200015020-00005
更新日期:2000-03-01 00:00:00
abstract::Nocturnal eating/drinking syndrome secondary to neuroleptic-induced restless legs syndrome (RLS) occurred under treatment with low-dose haloperidol in a 51-year-old female schizophrenic patient. Polysomnographic investigation showed a low level of sleep efficacy, periodic leg movements, and a strict relationship betwe...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:
更新日期:1999-01-01 00:00:00
abstract::The purpose of this study was to compare the efficacy and safety of risperidone and haloperidol in treatment-resistant chronic schizophrenic patients. Subjects (n = 78) who met DSM-III criteria for schizophrenia were randomly assigned to receive 6 mg/day of risperidone or 20 mg/day of haloperidol for 12 weeks. Clinica...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004850-200111000-00002
更新日期:2001-11-01 00:00:00
abstract::Social phobia was neglected by psychopharmacologically oriented researchers until the past decade. Benefitting from the experience with other anxiety and other affective disorders, however, and also from unique interdisciplinary collaborative arrangements between psychopharmacological and cognitive behavioral investig...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-199606003-00009
更新日期:1996-06-01 00:00:00
abstract::The negative symptoms of schizophrenia remain a major clinical challenge. Reboxetine is an antidepressant whose major mechanism of action is as a noradrenergic reuptake inhibitor. This study was a 6-week randomized placebo-controlled trial of reboxetine or placebo add on to haloperidol 5 mg in the treatment of 30 pati...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004850-200109000-00004
更新日期:2001-09-01 00:00:00
abstract::The aim of this study was to investigate the prevalence of benzodiazepine and related drug (BZDR) use, especially long-term use, and associated factors among community-dwelling individuals with and without Alzheimer's disease (AD). We utilized data from the MEDALZ-2005 cohort, which includes all community-dwelling ind...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0000000000000080
更新日期:2015-07-01 00:00:00
abstract::Negative symptoms are a key feature of schizophrenia. Novel (atypical) antipsychotic drugs, unlike conventional antipsychotics, cause substantial reductions in Positive and Negative Symptom Scale (PANSS) scores. Negative symptoms, however, can arise from both the pathology of the disease (primary negative symptoms) an...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-199803003-00008
更新日期:1998-03-01 00:00:00
abstract::While most depressed patients are prescribed a selective serotonin reuptake inhibitor (SSRI) as an initial treatment, the use of SSRIs as a second or third-line treatment for depression is not as prevalent. This trial assessed the efficacy of sertraline for patients with treatment-resistant depression (TRD) or patient...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00004850-200309000-00006
更新日期:2003-09-01 00:00:00
abstract::The DIABCARE Q-Net project developed a complete and integrated information technology system to monitor diabetes care, according to the gold standards of the St Vincent Declaration Action Program. This is the first Telematic platform for standardized documentation on medical quality and evaluation across Europe, which...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-200104003-00002
更新日期:2001-04-01 00:00:00
abstract::Predicting the outcome of treatment with neuroleptics and understanding the factors that contribute to variability in the response to these drugs have preoccupied researchers and clinicians since the class was developed. Clinicians need empirically based prospective criteria in order to choose a treatment strategy tha...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-199605002-00008
更新日期:1996-05-01 00:00:00
abstract::Treatment-resistant depression is an important clinical problem presenting a major challenge to clinical psychiatry. While several strategies have been attempted, including medication switch, antidepressant polypharmacy and various augmentative regimens, success remains limited. Amantadine (AMN), an agent traditionall...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00004850-200303000-00005
更新日期:2003-03-01 00:00:00
abstract::We report a case of myoclonus induced by quetiapine. A 64-year-old man with schizophrenia developed myoclonic jerks when given higher doses of quetiapine. These movements were dose-related and completely abated on reducing the dose. To our knowledge, these movements have not been reported previously as an adverse effe...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-200503000-00011
更新日期:2005-03-01 00:00:00
abstract::It has been suggested that the atypical antipsychotic drugs may induce a rapid improvement in individuals with melancholic depression. This might reflect a specific or non-specific effect on mood and other parameters. To examine this issue, ten consecutive patients, for whom olanzapine augmentation was judged a clinic...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00004850-200203000-00008
更新日期:2002-03-01 00:00:00
abstract::The aim of this study was to assess the response of social phobia (SP) symptoms to methylphenidate (MPH) treatment in children with attention deficit hyperactivity disorder (ADHD). Twenty-one ADHD patients with SP, aged between 8 and 18 years, received 12 weeks of MPH treatment. The severity of SP symptoms were assess...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0000000000000029
更新日期:2014-07-01 00:00:00
abstract::The selective serotonin reuptake inhibitors (SSRIs) have well-established antidepressant activity and have also demonstrated efficacy in a number of anxiety disorders, including panic disorder. The SSRIs, escitalopram and sertraline, are well-tolerated and movement disorders are rarely associated with their use. We pr...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-200505000-00010
更新日期:2005-05-01 00:00:00
abstract::Fourteen cases of depression resistant to multiple treatments were treated by lithium augmentation of fluoxetine. Tolerability of the treatment was poor. Lithium and fluoxetine may be a possible treatment for resistant depression but there is caution regarding tolerability and toxicity with the relatively high doses o...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-199400910-00005
更新日期:1994-04-01 00:00:00
abstract::This analysis characterizes patients with schizophrenia or schizoaffective disorder treated with risperidone who met remission criteria. In a 50-week, open-label trial, stable patients received long-acting injectable risperidone every 2 weeks. Remission criteria included severity (absent-mild ratings on core symptoms ...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/01.yic.0000224791.06159.88
更新日期:2007-01-01 00:00:00
abstract::Treatment of psychotic symptoms with traditional neuroleptics has been complicated by acute extrapyramidal syndromes (EPS) and late occurring tardive dyskinesia. These widely prevalent disorders have both motor and mental components which impose additional impairments on patients who are already substantially limited ...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-199702001-00004
更新日期:1997-02-01 00:00:00
abstract::The present study aimed to systematically compare overall loss to follow-up, discontinuation rates because of adverse events and discontinuation rates because of a lack of efficacy in published studies assessing the efficacy and tolerability of selective serotonin reuptake inhibitors (SSRIs) compared to other second-g...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,meta分析
doi:10.1097/00004850-200503000-00001
更新日期:2005-03-01 00:00:00
abstract::Amisulpride is a novel antipsychotic with a pharmacological and clinical profile that differs from that of other atypical agents. Amisulpride is highly selective for dopamine D2/D3 receptor subtypes located in the limbic region, which is highly predictive of potent antipsychotic activity with a low potential to cause ...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:
更新日期:2000-12-01 00:00:00
abstract::The objective of this study was to evaluate the effectiveness and tolerability of aripiprazole use in child and adolescent psychiatric inpatients. This was a naturalistic, retrospective evaluation of the discharged patients treated with aripiprazole on the child and adolescent unit at the Austin State Hospital. To be ...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0b013e3280119e0c
更新日期:2007-03-01 00:00:00